What is NDC 72205-054?

72205-054 is the product NDC for Fosaprepitant, Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.

Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.

What other NDCs exist for Fosaprepitant?

18 other product NDCs are listed under this name.

Is there a related HCPCS / J-code?

Not in Med-Code's curated HCPCS directory.

Fosaprepitant NDC 72205-054 | National Drug Code

NDC codes

FDA NDC Directory

Product NDC (as listed)72205-054Labeler and product segments. Claims need a package NDC.

Product NDC at billing width72205-0054Add the package segment from the table below.

Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC	11-digit (billing)	Package	Copy
72205-054-01	7220500540172205005401	1 VIAL, SINGLE-DOSE in 1 CARTON (72205-054-01) / 5 mL in 1 VIAL, SINGLE-DOSEMarketed from May 12, 2020

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary): Fosaprepitant
Generic name (nonproprietary): fosaprepitant
Active ingredients: Fosaprepitant dimeglumine — 150 mg/5mL
Dosage form: Injection, Powder, Lyophilized, For solution
Route: Intravenous
Labeler: Novadoz Pharmaceuticals LLCNDC labeler code 72205
Product type: Prescription drug
Marketing category: ANDA — Abbreviated New Drug Application (generic)Application ANDA 209965
Marketing start: May 12, 2020
Listing expires: Dec 31, 2027
Other FDA classes: Cytochrome P450 2C9 Inducers (Mechanism)Cytochrome P450 3A4 Inducers (Mechanism)Cytochrome P450 3A4 Inhibitors (Mechanism)Neurokinin 1 Antagonists (Mechanism)
Identifiers: Product ID 72205-054_604e47a7-2f8f-40f8-9595-00b09be51e40SPL ID 604e47a7-2f8f-40f8-9595-00b09be51e40SPL set ID 1e6b36b2-3c8b-4ac4-827e-d6f00d999032RxCUI 1731077UNII D35FM8T64XUPC 0372205054011
Pharmacologic class: Substance P/Neurokinin-1 Receptor Antagonist

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeNo match

No drug-specific HCPCS code in Med-Code's directory for this product. The directory is curated and not complete — check the current CMS HCPCS file before billing.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N472205005401 followed by a unit qualifier and the quantity

Package 72205-0054-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective Sep 30, 2022.

Indications (excerpt from the label)

Fosaprepitant for injection, in combination with other antiemetic agents, is indicated in adults and pediatric patients 6 months of age and older for the prevention of: • acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy (HEC) including high-dose cisplatin. • delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy (MEC). Limitations of Use • Fosaprepitant for injection has not been studied for the treatment of established nausea and vomiting. Fosaprepitant for injection is a substance P/neurokinin-1 (NK 1 ) receptor antagonist, indicated in adults and pediatric …

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

About NDC 72205-054

What is NDC 72205-054?: 72205-054 is the product NDC for Fosaprepitant, Fosaprepitant dimeglumine 150 mg/5mL injection, powder, lyophilized, for solution, listed with the FDA by Novadoz Pharmaceuticals LLC. It has 1 package NDC, shown above in 10- and 11-digit form.
What drug is associated with this NDC?: Fosaprepitant.
What is the active ingredient?: Fosaprepitant dimeglumine.
Who is the labeler?: Novadoz Pharmaceuticals LLC, NDC labeler code 72205. The labeler is the company responsible for the label; it may be the manufacturer, a repackager or a distributor.
What other NDCs exist for Fosaprepitant?: 18 other product NDCs are listed under this name. See all Fosaprepitant NDCs.
Is there a related HCPCS / J-code?: Not in Med-Code's curated HCPCS directory. See Billing references above.

Other finished products listed under the same name: strengths, forms and labelers.

Other Fosaprepitant NDCs
Product	Strength	Form · route	Labeler	Product NDC	Package NDCs (11-digit)
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/1	Injection, Powder, Lyophilized, For solutionIntravenous	Dr. Reddy's Laboratories Inc.,	43598-671	43598-0671-11
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	BluePoint Laboratories	68001-675	68001-0675-25
Fosaprepitantfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Avenacy, LLC	83634-776	83634-0776-10
Fosaprepitantfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	NorthStar RxLLC	16714-248	16714-0248-01
Fosaprepitantfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	BluePoint Laboratories	68001-523	68001-0523-36
Fosaprepitantfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Camber Pharmaceuticals, Inc.	31722-165	31722-0165-31
Fosaprepitantfosaprepitant dimeglumine	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	71731-5111	71731-5111-01
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Dr. Reddy's Laboratories Inc.,	43598-948	43598-0948-11
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Bryant Ranch Prepack	72162-2636	72162-2636-02
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Novadoz Pharmaceuticals LLC	72205-083	72205-0083-01

All 19 Fosaprepitant NDCs

Other NDCs under ANDA 209965

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under ANDA 209965
Product	Strength	Form · route	Labeler	Product NDC
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Dr. Reddy's Laboratories Inc.,	43598-859
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Dr. Reddy's Laboratories Inc.,	43598-948
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	BluePoint Laboratories	68001-675
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Bryant Ranch Prepack	72162-2636
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Novadoz Pharmaceuticals LLC	72205-083
Fosaprepitant	Fosaprepitant dimeglumine 150 mg/5mL	Injection, Powder, Lyophilized, For solutionIntravenous	Northstar Rx LLC	72603-450